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Background: Ebola hemorrhagic fever (Ebola) is still a highly lethal infectious disease long affecting mainly
neglected populations in sub-Saharan Africa. Moreover, this disease is now considered a potential worldwide
threat. In this paper, we present an approach to understand how the basic, clinical and patent knowledge on
Ebola is organized and intercommunicated and what leading factor could be shaping the evolution of the
knowledge translation process for this disease.
Methodology: A combination of citation network analysis; analysis of Medical heading Subject (MeSH) and
Gene Ontology (GO) terms, and quantitative content analysis for patents and scientific literature, aimed to map
the organization of Ebola research was carried out.
Results: We found six putative research fronts (i.e. clusters of high interconnected papers). Three research fronts are
basic research on Ebola virus structural proteins: glycoprotein, VP40 and VP35, respectively. There is a fourth research
front of basic research papers on pathogenesis, which is the organizing hub of Ebola research. A fifth research front is
pre-clinical research focused on vaccines and glycoproteins. Finally, a clinical-epidemiology research front related to
the disease outbreaks was identified. The network structure of patent families shows that the dominant design is the
use of Ebola virus proteins as targets of vaccines and other immunological treatments. Therefore, patents network
organization resembles the organization of the scientific literature. Specifically, the knowledge on Ebola would flow
from higher (clinical-epidemiology) to intermediated (cellular-tissular pathogenesis) to lower (molecular interactions)
levels of organization.
Conclusion: Our results suggest a strong reductionist approach for Ebola research probably influenced by the
lethality of the disease. On the other hand, the ownership profile of the patent families network and the main
researches relationship with the United State Army suggest a strong involvement of this military institution in Ebola
research.
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Ebola hemorrhagic fever (Ebola) is an acute viral disease
with high lethality rates [1], which overwhelmingly af-
fects populations in Sub-Saharan Africa [2]. The current
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the previous outbreaks combined [3].
Interestingly, Ebola is not considered a neglected trop-
ical disease, but it is rather classified as an acute and
emergent disease [4]. However, Ebola does shares three
key features with other diseases recognized as neglected:
first, this disease affects neglected populations, with no
access to a proper health care [5], as the current out-
break evidences. It has been reported that the “clinical
course of infection and the transmissibility of the virus
are similar to those in previous EVD outbreaks” [3].entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stable in the wild [6]. Therefore, the catastrophic dimen-
sion of the current outbreak could be mainly explained
by the impoverishing of the national health systems [5].
It has even been suggested that some punctual control
measures and a higher quality health system could have
avoided many deaths [3,5]. Second, in spite of the first
outbreak in 1979 [7], nowadays there are not approved
vaccines or drugs to help the affected population [8].
This lack of approved vaccines and drugs evidences that
innovation on Ebola has not been considered an attract-
ive enough business for the pharmaceutical industry
[9,10]. Finally, the third characteristic is that some
authors have suggested a racial stigmatization against
Sub-Saharan African-ancestry people as potential vectors
of Ebola [11-13]. The possible stigmatization of Africa as
an exporter of dangerous diseases like Ebola, is exempli-
fied [11] by Richard Preston’s non-fiction Bestseller “The
Hot Zone” [14]. In this regard, Haynes states that: “Pres-
ton exploits post-Cold War insecurities about African
contamination in the narrative structure of The Hot
Zone. By employing a long established discourse about
Africa as the “white man’s grave”, he inscribes these rare
filoviruses as a genuine biological threat to the people
and security of the United States” [11]. Meanwhile,
Murdocca states on the case of a patient wrongly diag-
nosed with Ebola in Canada in 2001 that “representation
of immigrants as vectors of disease is a useful and coer-
cive tool in the project of justifying immigration reform
and the state control of racial bodies” [12].
Besides these three aggravating features of Ebola, this
disease is frequently considered a threat to the US national
security [15,16]. Indeed, as an example, a US National
Intelligence Council document, published in 2000, identi-
fied Ebola as a global threat [17]. In fact, some authors
have even suggested the potential weaponization of the
Ebola virus [18,19]. Moreover, recently, the US President,
Barack Obama, stated in a letter addressed to the House
of Representatives (Emergency Appropriations Request
for Ebola for Fiscal Year 2015) the following:
“The request also includes resources to strengthen
global health security by reducing risks to Americans
by enhancing the capacity of vulnerable countries to
prevent disease outbreaks, detect them early, and
swiftly respond before they become epidemics that
threaten our national security” [20].
The neglected disease-like features and its condition
as a threat to the US security would be the main ele-
ments of the socio-political context of Ebola. We hy-
pothesized whether or not that these two elements
could be influencing the way we understand and re-
search Ebola. In this general context, this present pieceof research has two main objectives. The first is to ex-
plore how -for the first time- the knowledge on Ebola is
organized through the literature and patents networks.
The second, we have investigated some indications of
whether Ebola research is affected or not by the two
above elements.
To have a better perspective on how Ebola research is
organized, we have separated this exploration into three
more specific questions. First, which are the main research
fronts for Ebola and how they are intercommunicated. Re-
search fronts are clusters of highly interconnected papers
[21] putatively related to hidden colleges, i.e., virtual com-
munities of researchers who cited each other and work on
similar topics and share a similar way to research and
understand the problems. Second, how the basic, transla-
tional and clinical knowledge on Ebola is structured. Fi-
nally, what could be the dominant design for Ebola
according the structure of the patent families networks. A
dominant design is a system of paradigmatic and standard-
ized components or features within a particular product
class [22]. For example, pegylated liposomal doxorubicin, a
liposomal old drug, would be the dominant design for can-
cer nanotechnologies [23]. Because there are no approved
pharmaceutical treatments for Ebola yet, we decided to
consider as a dominant design the most prevalent techno-
logical option that simultaneously appears in the literature
and patent networks.
Methods
Our research is only based on the analysis of publicly
available secondary information: Abstracts of papers (all
of these are available in the Medical Literature Analysis
and Retrieval System Online MEDLINE© of the United
States National Library of Medicine) and the content of
patents (public documents which are available in The
United States Patent and Trademark Office (USPTO),
European Patent Office (EPO), the World Intellectual
Property Organization (WIPO) and other national pa-
tent offices). Therefore, this research did not require the
approval of an ethics committee. We have previously de-
veloped a combination of methodologies to explore the
network structure of scientific literature, which allows
identify the main research fronts of a certain field and
how these are interconnected each to other [23,24].
Also, these methodologies can map the knowledge trans-
lation process through the literature networks [23,24]. In
a previous research on liposomes for cancer therapy, we
adapted these methodologies to analyze patents net-
works [25]. The following steps of the above methodolo-
gies were followed in this study:
1. A search of research papers on Ebola was performed
in the Web of Science (WOS) [26] during October,
2014. The search criteria were the following: Title:
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Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S,
CPCI-SSH, BKCI-S, BKCI-SSH. We founded 752
papers.
2. We selected the 20% most cited papers (151). These
151 documents accumulated the 63% (18,260 of
28,970) of the citations that the 752 papers on Ebola
have received. It is important to point out that
citations in science tend to be distributed according
to a Zipf's law [27]. That is, a very small number of
papers receive a large quantity of citations, whereas
the most of papers have few citations or none. We
selected these 151 papers on Ebola because they are
a small, workable and readable number of papers
that accumulate most of the communication process
through the citations network.
3. The software Histcite [28] was used to build a
citation network model of the selected papers.
Cytoscape [29], an open source software, was used
as a platform for visualization and analysis of the
network model. Clust&See [30], a Cytoscape plug-in,
was used to divide the network model in clusters
(according to the Newman modularity that defines
clusters as “groups of vertices within which
connections are dense but between which they are
sparse” [31]), which are putatively related to different
research fronts.
4. The selected papers were searched in GOPubmed
[32]. This search engine semantically analyzed the
papers (title and abstract) and labeled them with
Gene Ontology (GO) [33] and Medical Subject
Heading (MeSH) [34] terms. We a priori defined as
clinical terms all MeSH terms that belong to the
next higher hierarchy categories: “Diagnosis”,
“Therapeutics”, “Surgical Procedures, Operative”,
“Named Groups”, “Persons” and “Health Care”. We
calculated the rate of clinical terms vs. non-clinical
for every paper in the citation network model. The
MeSH and GO terms that were common for most
of the papers of each cluster were identified. The
most characteristic of these GO and MeSH terms
were used to label and differentiate the clusters.
5. The modes (papers) were colored according to a
color (from red to blue), which is a function of the
clinical terms rate. The network model was
displayed using the “spring embedded” algorithm.
6. The abstracts of the papers in the network model
were analyzed using KH Coder, a software for
quantitative content analysis [35-37]. KH Coder was
used to perform two different analyses in order to
compare the content of the clusters. First, the top 10
distinctive world of each cluster were identified
using the Jaccard index as a distinctiveness measure.
Second, a correspondence analysis was performed.“Correspondence analysis is a descriptive/
exploratory technique that uses a simple two-way
and multi-way contingency table” [37].
7. A search of patent families (i.e. a set of patents that
refers to the same invention) were performed in the
Derwent Innovations Index [38] during October,
2014. The search criteria were the following: TITLE:
Ebola; Timespan: All years; Indexes: CDerwent,
Ederwent and MDerwent. We founded 102 patents.
We selected the 20% most cited of the patent
families (21) which received 77.6% of the citations
(146 of 188). Note that we are just considering
citations among patent families without citations
from other sources, like research papers.
8. We build a network model of inter-citation for the
selected patent families. The model was visualized
using Cytoscape. AllegroMCODE [36] was used to
identify highly interconnected (dense) regions of the
network model. These dense regions are related to
types of inventions that could share the same
inventors or assignees.
9. The title and abstract of the patent families in the
network model were analyzed using the semantic
annotator of GOPubmed. The main MeSH and GO
terms associated with the network model and dense
regions were identified.
Results
We built two different semantically analyzed network
models (maps). The first map displays the general struc-
ture and inter-communication of basic, translational and
clinical research on Ebola, while the second map shows
how the patented knowledge is structured and what
could be the dominant design for anti-Ebola therapy.
These maps are separately described in what follows.
Ebola research map
A citation network of 150 top cited papers on Ebola was
built (Figure 1). Clust&See divided the network in seven
clusters (Figure 1). These clusters of papers are mainly or-
ganized around three structural proteins of the Ebola virus,
according to the GO andMeSH terms distribution (Figure 1
and Table 1). Also, there are a cluster of epidemiological-
clinical papers around the term “disease outbreak” and one
cluster of papers on pathogenesis. The clusters are num-
bered according to their size rank and named with their
most representative GO or MeSH terms.
Cluster 1 consists of 33 papers and 173 inter-citations.
These papers exhibited an average rate of clinical terms
of 1.4%. The GOPubmed terms that distinguish this
cluster are “glycoproteins” and “viral envelope” (Table 1).
14 of these papers were published in the Journal of
Virology. The paper with the highest in-degree (the most
cited by the papers in the cluster) is “The virion
Figure 1 Network model of research papers on Ebola. Each node represents one paper of the 20% most cited papers on Ebola, and the edges
represent the citations between the documents. The shape of the nodes indicates to which cluster (research front) they belong. The color of the
nodes is according to a continuous scale from red to blue. This scale is a function of the clinical terms rate, so a red node could be considered a
basic research paper, a purple one translational research, and a blue node is a clinical observation article.
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ing frames and are expressed through transcriptional
editing” [6]. Cluster 1 papers clearly form a basic re-
search front organized around the Ebola virus structural
glycoprotein.
Cluster 2 consists of 31 papers and 147 inter-citations.
These papers exhibited an average rate of clinical
terms of 11.8%. Its distinguishing GOPubmed terms
are “immunization”, “vaccunation”, “vaccines” and “gly-
coproteins” (Table 1). Peter Jahrling, currently Chief
Scientist at The USA National Institute of Allergy and
Infectious Diseases (NIAID), is author of 14 of these
papers. The papers with the highest in-degree are “A
Mouse Model for Evaluation of Prophylaxis and Therapyof Ebola Hemorrhagic Fever” [39] and “Immunization
for Ebola virus infection” [40]. The latter paper re-
ported an research about the Ebola nucleoproteins and
glycoproteins ability to protect against infection. Clus-
ter 2 papers are mainly pre-clinical research focused
on the discovery of potential immunotherapies based
in glycoproteins and other molecular entities.
Cluster 3 consists of 23 papers and 117 inter-
citations. The average rate of clinical terms is 4.4%.
“Pathogenesis” is the distinguishing GOPubmed term
(Table 1). Thomas Geisbert, Professor, Microbiology
& Immunology, is coauthor of 9 papers belonging to
this cluster. It is important to note that his laboratory
“focuses on the pathogenesis of emerging and re-
Table 1 Main GO and MeSH terms of each cluster
Main GO and MeSH terms Number of papers
Cluster 1
Ebolavirus 33
Viruses 32
Glycoproteins 31
Humans 26
Viral envelope 24
Animals 23
Cell Line 18
Cluster 2
Ebolavirus 30
Animals 30
Viruses 30
Hemorrhagic Fever, Ebola 28
Immunization 20
Vaccination 20
Vaccines 20
Immunity 18
Mice 18
Glycoproteins 18
Antibodies, Viral 15
Humans 15
Hemorrhage 15
Cluster 3
Viruses 19
Ebolavirus 19
Humans 13
Animals 13
Hemorrhagic Fever, Ebola 12
Pathogenesis 12
Cluster 4
Ebolavirus 14
Humans 14
Viruses 13
Hemorrhagic Fever, Ebola 12
Disease Outbreaks 11
Cluster 5
Viruses 14
Ebolavirus 13
Proteins 13
Humans 10
Viral Proteins 9
Retrotransposon nucleocapsid 9
Matrix protein VP40 9
Table 1 Main GO and MeSH terms of each cluster
(Continued)
Virion 9
Virus assembly 9
Cluster 6
Viruses 13
Ebolavirus 12
Humans 10
Viral Proteins 9
Genes 9
Proteins 9
Animals 9
Interferons 8
Polymerase cofactor VP35 8
Virus Replication 8
RNA 8
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containment and on the development of countermea-
sures against these viruses” [41]. The paper with the
highest in-degree is “Association of Ebola-related Res-
ton virus particles and antigen with tissue lesions of
monkeys imported to the United States” [42]. This
cluster consists of basic research papers mainly fo-
cused on pathogenesis.
Cluster 4 consists of 22 papers and 76 inter-citations.
The average rate of clinical terms is 27.8%. “Disease out-
breaks” is the distinguishing GOPubmed term (Table 1).
The paper with the highest in-degree is “Isolation and
partial characterization of a new strain of Ebola virus”
[43]. It is important to note that this paper reported “the
first time that a human infection has been connected to
naturally-infected monkeys in Africa” [40]. Cluster 4 is
clinical-epidemiological set of papers focused on Ebola
disease outbreaks. Thomas Ksiazek, Director of high
containment laboratory operations for the Galveston Na-
tional Laboratory at the University of Texas, is the main
author of this cluster. He is the author of 9 papers in
cluster 4.
Cluster 5 consists of 17 papers and 66 inter-citations.
The average rate of clinical terms is 1.9%. Its distinguish-
ing GOPubmed terms are “retrotransposon nucleocap-
sid”, “matrix protein VP40”, “vrion” and “virus assembly”
(Table 1). The papers with the highest in-degree are
“Vesicular release of Ebola virus matrix protein VP40”
[44] and “Ebola virus VP40-induced particle formation
and association with the lipid bilayer” [45]. Cluster 4 is
basic research focused in the Ebola virus structural pro-
tein VP40.
Cluster 6 consists of 15 papers and 51 inter-citations.
The average rate of clinical terms is 1.2%. Its distinguishing
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VP35” and “virus replication”. The papers with the highest
in-degree are “Comparison of the transcription and repli-
cation strategies of Marburg virus and Ebola virus by using
artificial replication systems” and “The Ebola virus VP35
protein functions as a type IIFN antagonist” [46]. Cluster 4
is basic research focused in the Ebola virus structural pro-
tein VP35.
Cluster 7 consists of 9 papers and 19 inter-citations.
The average rate of clinical terms is 1.2%. The Gopubmed
terms are shared with the rest of clusters, i.e., they are too
general to consider cluster 7 related to a putative research
front.
Figure 2 summarizes how these cluster are organized
together. Each node represent one cluster and the ar-
rows are formed by the sum of the inter-citations be-
tween two clusters. In order to make it more readable,
we hid the links formed with less than 30 inter-citations.
Cluster 3 (pathology) is the hub of the Ebola research
map. The strongest connection is between cluster 3 and
cluster 2 (vaccines and glycoproteins). The second stron-
gest connection is between cluster 1 (glycoproteins and
viral envelope) and cluster 3. The basic and pre-clinical
researchs on glycoproteins (clusters 1 and 2) are connectedFigure 2 Main interactions among the research fronts. Each node represen
arrows represent the sum of the inter-citations between two clusters. The p
each cluster cited other. The direction of the arrows represents the direction oby the third biggest inter-citation. Clusters 6 (VP35) and 4
(disease outbreaks) are mainly connected to cluster 3.
Cluster 4 (VP40) is mostly connected to cluster 1. Cluster
7 is just an appendix of cluster 1. The citations among the
clusters show a directionality from cluster 4 “disease out-
breaks” to cluster 3 “pathogenesis” to the clusters that are
related to Ebola virus proteins.
110 papers of the network model were coauthored by
researchers working in The United States of America.
Qualitative content analysis of the clusters
The qualitative content analysis is consistent with that
observed in the GO and MeSH term distribution
(Table 1). Cluster 4 most distinctive words are “out-
break”, “patient”, “case” and “human” (Table 2). The
correspondence analysis plot showed that cluster 3
has the most similar content to cluster 4 (Figure 3).
This matches with the fact that cluster 4 is mainly
connected to the rest of the citation network through
cluster 3 (Figure 2). The GO and MeSH terms and the
quantitative content analysis suggested that cluster 4
is related to a clinical-epidemiological research front
on Ebola. Cluster 3 most distinctive words are “cell”,
“infection”, “level”, “response”, “viral” and “endothelial”ts one of the 6 clusters meaningfully related to research fronts. The
air of numbers inside the arrows represents the number of times that
f the most of the citations, i.e. the arrows point to the most cited cluster.
Table 2 List of the top 10 distinctive world of each cluster
Cluster 1 Distinctiveness Cluster 2 Distinctiveness Cluster 3 Distinctiveness Cluster 4 Distinctiveness
GP .277 Vaccine .273 Cell .153 Outbreak .216
Cell .222 Ebola .210 Infection .131 Patient .186
Virus .201 Virus .202 Level .102 Case .164
Glycoprotein .177 Challenge .163 Response .099 Human .096
Ebola .167 Protect .154 Viral .098 Antigen .093
Entry .130 Lethal .143 Endothelial .084 Hemorrhagic .091
Viral .088 Infection .134 Replication .079 Fever .090
Fusion .086 Mouse .122 Patient .077 Assay .090
GP2 .081 Antibody .108 Study .076 Serum .087
Surface .072 Animal .102 Macrophage .076 Antibody .087
Cluster 5 Distinctiveness Cluster 6 Distinctiveness
VP40 .406 Protein .144
Bud .254 EBOV .136
Protein .200 VP35 .133
Particle .156 Gene .094
Motif .143 RNA .093
Membrane .126 Interferon .087
Assembly .121 VP24 .083
Ebola .116 IFN .082
Matrix .106 Response .079
vlp .106 Activation .078
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3 in a intermediate position between cluster 1 and
cluster 4 (Figure 3), which resembles the inter-citation
structure among the clusters (Figure 2). The quantita-
tive content analysis and the GO and MeSH terms
distribution suggest that cluster 3 is basic research
focused on the host immune system-virus pathogenic
interaction. Clusters 1, 5 and 6 most distinctive words
are related to molecular-level concepts like “Glycopro-
tein”, “virus”, “VP40” (Viral protein 40), “particle”,
“motif”, “VP35” (Viral protein 35) or “interferon” (Table 2).
These three clusters are practically equidistant in the
concurrence analysis plot (Figure 3). According to the
MeSH and GO terms distribution and the quantitative
content analysis, these three clusters are basic research
focused on the interaction of the viral proteins and
the molecular machinery of the host immune cells.
Finally, cluster 2 most distinctive words are “vaccine”,
“ebola”, “virus”, “challenge”, “protect” and “lethal” (Table 2).
Cluster 2 is located far away from the other ones in
the correspondence analysis plot, i.e., its content is
quite different from the rest of clusters. The distribution
of MeSH and GO terms (Table 1) and the qualitative
content analysis (Table 2 and Figure 3) suggest that clus-
ter 2 is translational research focused in the development
of vaccines.Ebola patenting map
16 of the selected patent families form four small and
simple networks (Figure 4). AllegroMCODE identified
just one densely connected region formed by four patent
families (Figure 4, yellow nodes). The United States Sec-
retary of the Army is the leading assignee in this central
region (Figure 4). A more recent search (December
2014) in the Derwent Innovations Index show that pa-
tent families in the densely connected region are the first
(Derwent Primary Accession Number, DPAN: 2000–
160677), second (DPAN: 1999–405117) and fourth
(DPAN: 2004–226835) most cited. The semantic analysis
showed these four inventions are related to vaccine de-
velopment, antibodies and viral DNA (Table 3). Basic
Gopubmed terms like “Infection”, “Cells” and “viral
reproduction” are commons to the most of the 16 inter-
connected patent families (Table 3).
Discussion
Elements for the interpretation of results
We consider that there are two necessary conceptual el-
ements to interpret our results. First of all, we searched
for papers and patent families with the world “Ebola” in
their titles. We did not a priori search for papers on
pathogenesis of Ebola disease, Ebola virus genome or
health policy research on Ebola, we searched just for
Figure 3 Plot of the correspondence analysis of the clusters. The euclidean distance among the clusters is a measure of the similarity of their
word distribution. Also, the top 60 words filtered by their chi-square value were plotted. These words are representative of the closest clusters.
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ments. Scientific communication has a hegemonic struc-
ture reflexed in the power law distribution of its
citations [27]. Hegemony in science means that there are
some ideas or concepts much more influential than
others. The most cited papers citing each other consti-
tute the paradigmatic and hegemonic body of a particu-
lar field of study. Similarly, the most cited inventions
trend to show what the dominant design is. An add-
itional element is that certain concepts are related to
particular research fronts. Therefore, in this research welooked for the ideas, research fronts and technological
strategies that form the paradigmatic view of Ebola. We
discuss below how this paradigm is organized and how
the nature and context of Ebola (as a acute disease
affecting neglected populations and a national-global se-
curity threat) partially explains its knowledge structure.
The big picture of Ebola research
Figure 2 illustrates how this paradigmatic view is struc-
tured. We identified two relevant features in the literature
network model. Firstly, the reductionist directionality of the
US ARMY MEDICAL RES 
INST INFECTIOUS DISE 
US SEC OF ARMY
US ARMY MEDICAL RES 
INST INFECTIOUS DISE; 
US SEC OF ARMY 
BRIGHAM & WOMENS 
HOSPITAL INC 
UNIV MICHIGAN; US 
DEPT HEALTH & HUMAN 
SERVICES
UNIV PENNSYLVANIA
CRUCELL HOLLAND BV; 
US DEPT HEALTH & 
HUMAN SERVICES; US 
SEC OF NAVY; US 
GOVERNMENT
US MEDICAL RES INST 
INFECTIOUS DISEASES 
US SEC OF ARMY 
PROTIVA
BIOTHERAPEUTICS INC; 
UNIV BOSTON; US ARMY 
ALNYLAM PHARM INC;
US SEC OF ARMY; US 
SEC OF HEALTH; 
BIOCRYST PHARM INC
BIOCRYST PHARM INC
BIOCRYST PHARM INC
POWDERJECT VACCINES 
INC
BIOCRYST PHARM INC
US ARMY MEDICAL RES 
INST INFECTIOUS DISE 
Figure 4 Network of patent families related to Ebola. Each node is a patent family. They are named by their assignees. The nodes in yellow and
their inter-citation form a densely connected region identified by the application AllegroMCODE [68].
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the knowledge seems to flow from “disease outbreaks” (A
population-to-individual level research front) to “pathogen-
esis” (A cellular level research front) to the viral protein-
related research fronts (biomolecular level). Secondly, the
only one research front that is related to the development
of potential therapeutic alternatives (cluster 2 “vaccines”) is
at a cellular-biomolecular level and this research front
strongly cites papers belonging to the “glycoprotein” and
“pathogenesis” research fronts. These two features are dis-
cussed in detail next.
The reductionist directionality and the contextualization
Apparently, there is a reductionist directionality among
the research fronts from higher to lower organization
levels (Figure 2). The exception could be the interactionbetween clusters 3 and 1, which is mostly bidirectional.
Reduction means that a more complex phenomenon is
explained by the interaction of other phenomena in a
simpler or more fundamental level. Thus, “Disease out-
breaks” research (Cluster 4) is, in a way, the phenom-
enological description of the disease that should be
explained by the more fundamental “pathogenesis” re-
search (Cluster 3). In turn, the “pathogenesis” pheno-
menon would be explained by the research on the
structural Ebola virus proteins GP, VP40 and VP35
(Clusters 1, 5 and 6 respectively). On the other hand,
“pathogenesis” research would be contextualized by the
“disease outbreaks” research, and viral proteins research,
in turn, would be contextualized by the “pathogenesis”. In
this research, contextualization means that the interac-
tions occurring in a lower lever are correctly interpreted
Table 3 Main GO and MeSH terms of the all connected
patent families and the densely connected region
Main GO and MeSH terms Number of papers
All the connected patent families
Viruses 16
Ebolavirus 15
Infection 11
Cell 10
Cells 10
Viral reproduction 10
Acids 8
Methods 8
RNA 8
Vaccination 8
Vaccines 8
The densely connected region
Biosynthetic process 4
Ebolavirus 4
Vaccination 4
Vaccines 4
Viruses 4
Acids 3
Antibodies 3
Antibodies, Viral 3
Antigen binding 3
Cell 3
Cells 3
DNA 3
DNA, Viral 3
Host 3
Infection 3
Viral reproduction 3
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phenomenon. In order to clarify the idea of contex-
tualization a passage of a paper written by Thomas W.
Geisbert et al. is used as an example (this paper belongs to
the cluster 3 “pathogenesis”):
“Animal models that adequately reproduce human
EBOV HF are clearly needed to gain further insight
into the pathogenesis of this disease. […] two rodent
models of EBOV infection are not ideal for studying
human EBOV HF; neither mice nor guinea pigs
exhibit the hemorrhagic manifestations that
characterize human EBOV infections” [47].
This paragraph clearly notes that the disease manifest-
ation in the patient is the context of Ebola pathogenesis.The discoveries at the cellular and molecular levels are
relevant, useful and meaningful as long as animal
models resemble the disease in the patients. So, because
of the context, we could consider that cynomolgus
macaque is a more adequate animal model for Ebola re-
search than rodent models. On the other hand, the dis-
ruption of the behavior of some types of leukocytes
provoked by Ebola virus is a key component of the ex-
planation of Ebola disease.
This kind of “reduction-contextualization” relationship
could be also observed between “pathogenesis” and the
viral proteins research fronts. A example of this type of
relation is noted in a paper of cluster 6 “polymerase
cofactor VP35” citing another document of cluster 3
“pathogenesis”.
Mahanty et al. state in a paper belonging to the
“pathogenesis” the next conclusion (Please note that DC
is the abbreviation of dendritic cells in the passage):
“Ebola and Lassa viruses infect human monocyte-
derived DC and impair their function […] These data
represent the first evidence for a mechanism by which
Ebola and Lassa viruses target DC to impair adaptive
immunity” [48].
Basler et al. cited the previous paper in this paragraph:
“Ebola virus infection has recently been reported to
impair human dendritic cell function. It is possible
that the ability of VP35 to inhibit IFN production may
contribute to the ability of Ebola virus to inhibit
dendritic cell functions” [49].
Dendritic cells impairment by Ebola virus is a key
element of the explanation of Ebola disease. However, a
reductionist approach requires a more fundamental (bio-
molecular) explanation: VP35 inhibition of anti-viral
genes could be a factor that explains the dendritic im-
pairment and therefore these could be fundamental to
understand Ebola disease. Oppositely cellular behavior
and communication are the context of research on
VP35.
From lab bench (glycoprotein) to bedside (vaccines)
According to our results, Ebola research does not have a
applied clinical research front, unlike cancer research.
However, it does have a pre-clinical or translational re-
search front focused on vaccines development with virus
glycoprotein as the main target: Cluster 2 “vaccines”
(Figures 1, 2, 3 and Tables 1 and 2). The papers on vac-
cines strongly cite “pathogenesis” and “glycoproteins”
documents (Figure 2). These results suggest that the de-
velopment of medical interventions for Ebola disease are
only considering the knowledge at the cellular-molecular
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communication among these. That is, the reductionist ap-
proach is dominating the knowledge translation process
(NT). It is important to note that we operatively define NT
as the communication between basic (discovery) research
and applied clinical research through the inter-citation
[23,24]. In the case of Ebola research, KT would be the
inter-communication that the “vaccines” research front has
with “pathogenesis” and “glycoproteins”. A couple of exam-
ples of “vaccines” papers citing documents of the two basic
research fronts are briefly analyzed below.
The first example shows how the knowledge on apoto-
sis impacts on the development of vaccines. A “patho-
genesis” paper reported that massive apoptosis happened
in fatal human Ebola disease as follows:
“We compared the immune responses of patients
who died from Ebola virus disease with those who
survived […] DNA fragmentation in blood
leukocytes and release of 41/7 nuclear matrix
protein in plasma indicated that massive
intravascular apoptosis proceeded relentlessly during
the last 5 days of life” [50].
The above research is cited by a “vaccines” paper in
order to argument that primate models are more
suitable than rodent models for vaccine testing. Here the
citing paragraph:
“..rodent models of EBOV hemorrhagic fever do not
consistently predict efficacy of candidate vaccines in
nonhuman primates […] Lymphocyte apoptosis was
not reported to be a prominent feature of EBOV
infection in mice or guinea pigs but was a consistent
feature of disease in humans and nonhuman
primates” [51].
These two previous paragraphs show how reduction-
ism is influencing the KT process in Ebola research.
That is, differences and similarities between humans and
animal models at the cellular-molecular level, like the
lymphocyte apoptosis, are what would predict the suc-
cess or failure of a treatment.
An important part of the knowledge translation
process (the interaction between clusters 1 and 2) is
dominated by the research on one single biomolecule:
the Ebola virus glycoprotein. The glycoprotein is simul-
taneously considered the key determinant of Ebola dis-
ease and the main component in the development of
anti-Ebola vaccines. A cluster 2 of papers citing a cluster
1 document provides an example of the importance of
this viral protein.
Yang et al. reported the importance of the glycoprotein
mucin domain to explain the pathogenesis as follows:“…synthesis of the virion glycoprotein (GP) of Ebola
virus Zaire induced cytotoxic effects in human
endothelial cells in vitro and in vivo […] These
findings indicate that GP, through its mucin
domain, is the viral determinant of Ebola
pathogenicity and likely contributes to hemorrhage
during infection¨ [52].
Martin et al. employed the above mentioned know-
ledge in order to design a safer glycoprotein-based vac-
cine through deletions in the pathogenic region of the
viral protein. The citing paragraph is:
“The Ebola virus GP genes expressed by plasmid DNA
constructs in this vaccine contain deletions in the
transmembrane region of GP that were intended to
eliminate potential cellular toxicity observed in the
in vitro experiments using plasmids expressing the
full-length wild-type GPs” [53].
Finally, is important to notice that the reductionist
biomolecular approach of Ebola research is necessarily
coordinated with pharmaceutical strategies of interven-
tion, like vaccines and other immunotherapies. Accord-
ing to our patents and scientific literature analyses,
vaccines are the dominant design for Ebola, i.e., they are
the hegemonic strategy to fight Ebola (see Figures 1, 2, 3
and Tables 1, 2, 3). Importantly, this strategy is funda-
mentally based on pre-clinical knowledge. In this re-
search we did not find an organized body of clinical
evidence (i.e., controlled trials, cohort studies or eco-
logical studies). Instead, we found an organized body of
mechanistic or pre-clinical evidence (rodent models and
experiments involving non-human primates): the cluster
2. Previously, we had identified a full knowledge transla-
tion process for cervical cancer [54] and cancer nano-
technologies [23,24], i.e., basic research connected to
clinical research through a translational research field.
This is not the case with Ebola research, which has an
incomplete knowledge translation process. This is im-
portant because the level of evidence is a key factor for
decision-making in health [55]. Currently, there is a de-
bate on the ethical use of experimental intervention on
Ebola [56]. Some authors consider ethically valid the use
of vaccines even though there is not clinical evidence to
support it [57]. They consider that the dramatic dimen-
sion of the current outbreak makes the experimental
pharmaceutical interventions necessary [57]. However,
because these experimental interventions could imply
unknown health risks [58] it is important to examine how
the knowledge on Ebola is organized and who are the dom-
inant stakeholders that influence its organization. Our re-
sults indicate that the US Army is the main assignee and
the main research institution on Ebola. Particularly, the
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Army researchers in the clusters 2 and 3 suggest a possible
connection between a national security paradigm and a
highly sophisticated reductionist approach. In this regards,
Colonel Erin P. Edgar commander of the United States
Army Medical Research Institute of Infectious Diseases
state the following:
“…it is also clear that USAMRIID plays a critical role
in the status of our country's preparedness for
biological terrorism and biological warfare. While our
primary mission is to protect the warfighter, our
research benefits civilians as well” [59].
If these experimental intervention on Ebola were ori-
ginally designed to satisfy the requirement of a national
security agenda, how then we could be sure that these
immunological technologies are the best option for the
people of Sub-Saharan countries affected by the current
outbreak?
The reductionist approach and the lethal nature of Ebola
disease
Unlike research on cancers and possibly other chronic
diseases, it is difficult to study the Ebola disease as a
condition of the patient (clinical knowledge). That is, in
the case of Ebola there are not yet organized research
fronts on treatment outcome (humans), survival, health
policy or quality of life because of the acute and lethal
nature of the disease. There is not enough time to focus
on the patient suffering an acute disease unlike chronic
diseases, which could last years. Ebola lethality could be
enhancing a reductionist approach to study the disease
mainly through two mechanisms. Firstly, biosafety level
4 requirement to work with Ebola virus could hamper
some studies [60]. In order to avoid that problem
researchers disassemble the Ebola virus to separately
work with the structural proteins. For example, re-
searchers uses recombinant vesicular stomatitis virus
[60], replication-deficient adenovirus [61] or a plasmid
containing genes of viral proteins [62]. Secondly, rodent
models are the most feasible for high security biocon-
tainment facilities [63] but they do not properly resem-
ble the disease in human as non-human primates do
[63,64]. Some mouse models are genetically modified in
order to study specific molecular-cellular interaction
among the virus and the host [63,64]. That is, the use of
genetically-modified mouse model furthers the partition
of the knowledge on the disease in molecular interaction
and then synthetically rebuilds the pathogenesis (the
whole) through the parts.
The reductionism approach of Ebola research may be
lessened in the future due to two fundamental events:
The emergence of approved and effective anti-Eboladrugs, and the current outbreak (2013–2015). First, the
availability of pharmaceutical countermeasures could in-
crease the chances of survival of the patients. In turn,
higher survival rates would allow the emergence of re-
search fields focused in the patient. Second, the dramatic
differences between the current and the previous out-
breaks can not be explained by biological phenomena
but socioeconomic and environmental changes affecting
the national health systems of the affected countries.Involvement of the US Army in Ebola Research &
Development (R&D)
Two of our results suggest that Ebola R&D is influenced by
the fact that Ebola disease is consider a national or global
security threat, i.e., Ebola disease would be a military inter-
est. The first result is that the main assignee in the patent-
ing network is the United State Army (Figure 2). The
second result is the overwhelming leadership of the United
States in Ebola Research (110 of 150 top papers are
authored by a researchers based in that country). The three
most important authors of Ebola research namely, Peter
Jahrling, Thomas Geisbert and Thomas Ksiazek (they are
the leaders of clusters 2, 3 and 4, respectively) are or have
been related to the United States Army Medical Research
Institute of Infectious Diseases. It is clear the relevant par-
ticipation of the US army in the Ebola R&D. But the im-
portant question is whether this implication of the Army is
affecting the way Ebola is researched and understood. Our
results suggest, at least, a possible relation between reduc-
tionism and the involvement of the US Army in Ebola re-
search. The central and organizing patent family (DPAN:
2000–160677), which is owned by the United State Army,
reported as an invention key epitopes and sequences of the
structural viral proteins GP, NP, VP24, VP30, VP35 and
VP40. The GO and MeSH terms related to the patents
families (Table 3) that are mainly owned by the US army
show that the inventions are conceptualized at a molecular-
cellular level. Using Ebola virus proteins as a target of vac-
cines and other immunotherapies is the dominant design
that could be being promoted by the military institution.
Ebola shares key features with neglected diseases. The
social dimension of Ebola and the lethal nature of the
disease could partially explain why there is not currently
research focused in the patient and the observed reduc-
tionist and military orientation of Ebola research. Ebola
R&D is not an attractive business to the pharmaceutical
industry because its too expensive and there is not a
large enough market [9,10]. However, Ebola is still con-
sidered a threat to the national security of United States
ant therefore Ebola research is powered with public
funds through the US army [65]. The US army, the main
assignee, is currently looking for the development of
drugs and biotechnological tools, a sort of magic bullets,
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reductionist approach.
The gap between Ebola research and the multiple
stakeholders expectancy
Previously, we have mentioned that the hegemonic
knowledge on Ebola is mainly aimed to satisfy the re-
quirement of a national security agenda. However, there
is a plethora of stakeholders at different levels that could
need different technological alternatives and approaches
on Ebola: the affected communities, women, children,
local governments, neighbor countries, the African
Union, the Word Health Organization, the US govern-
ment, etc. In this regard, Daniel Sarewitz and Roger A.
Pielke Jr. conceptualized the relationship between the
supply and demand of knowledge with two key ques-
tions in a 2x2 matrix: 1) “Is relevant information pro-
duced?” 2) “Can user benefit from research?” [66]. We
could use these two questions as a conceptual tool to
evaluate current research topics and propose new re-
search strategies for Ebola. For example, sophisticated
immunotherapies to treat and control Ebola can be very
relevant research topics but they could be too expensive
and difficult for mass production. So, some putative
users could be “marginalized”. If this were the case, two
research strategies should be raised: the first would be
aimed to improve the accessibility of immunotherapies
while the second one would aimed to develop more
accessible and suitable technological alternatives for the
neglected stakeholders.
Matthew L. Wallace and Ismael Rafols propose that
global maps of science -a scientometrics analysis tool-
could “provide a sense of the range of existing theories
and methodologies” (supply of knowledge) “with a
connection to a given set of outcomes” (demand of
knowledge) “which is conducive to identifying potential
gaps and positive interactions” [67]. We consider that a
combination of the methodologies used in the present
paper with the use of global map of science could be a
powerful strategy for analysis and management of the
relation between the supply and demand of knowledge
of multiple stakeholders.
Conclusions
For the first time we have mapped the hegemonic struc-
ture of basic, clinical and patented knowledge on Ebola
research. Our results suggested that Ebola research is or-
ganized around a reductionist paradigm. Three viral pro-
teins, particularly the Ebola virus glycoprotein, and their
interaction with the host immune system cells are at the
core of the explanation of the disease. The involvement
of the US Army is a important feature of Ebola research.
The US Army is the main assignee of anti-Ebola inven-
tions and the leading researchers are or have beenrelated to this military institution. The lethality of Ebola
and its condition as a neglected disease could be the main
influence behind the reductionism and militarization of
Ebola research. The knowledge structure of Ebola may be
modified in the future by two fundamental events: The
emergence of approved anti-Ebola treatments and the
current outbreak (2013–2015) booting the clinical and pub-
lic health research fields. Further research on the putative
changes in the knowledge structure of Ebola would be
relevant.
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